Natera (NTRA) announced the launch of the TEODOR trial. TEODOR is a Phase II, multicenter, randomized controlled trial that aims to replace chemotherapy with endocrine therapy prior to surgery for a subset of women with hormone receptor-positive, HER2-negative breast cancer, who are endocrine responsive and test negative with Signatera.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA: